drugset / Trial / NCT04424966
Infigratinib in Recurrent High-Grade Glioma Patients
Phase 0
Terminated
7 enrolled
Nader Sanai
Barrow Neurological Institute · collabIvy Brain Tumor Center · collabQED Therapeutics, a BridgeBio company · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation which are scheduled for resection. In the lead-in cohort, a total of 20 participants will be enrolled into the proposed phase 0 clinical trial. Participants will be administered infigratinib prior to surgical resection of their tumor.
Timeline
- Start
- 2020-07-21
- Primary completion
- 2023-01-31
- Completion
- 2024-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infigratinib | Small molecule | 125 mg | Oral |